GoAI
Get started
Qianhai Health Holdings Limited logo

Qianhai Health Holdings Limited

0911.HK

HKSEHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Latest quote

HK$0.535

−HK$0.005 · -0.93%

Aug 21, 6:07 PM HKT

0911.HK company overview

Historical prices · Market data may be delayed.

Company profile

Company website

Qianhai Health Holdings Limited (0911.HK) functions as an investment holding company primarily focused on the distribution of health products and electronic components within Hong Kong. Its operations are structured into two main divisions: Health-Care Products and Electronic Component Products. The Health-Care Products segment supplies a range of items, including Chinese herbal medicines, various skincare and wellness products, and American ginseng, catering to both wholesale and retail clients. Concurrently, the Electronic Component Products division deals in items such as central processing units (CPUs) and semiconductors. Beyond these primary sales, the company also engages in the trading of both its health-care and electronic component offerings, alongside a money lending business. Established in 1989, the company underwent a name change in September 2016 from its previous identity, Hang Fat Ginseng Holdings Company Limited. It is headquartered in Sheung Wan, Hong Kong, and operates as a subsidiary of Explorer Rosy Limited.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
HK
CEO
Chee Lap Yuen
Listed since
Jun 27, 2014
Employees
19

Market position

Day range

Current HK$0.535

52-week range

Current HK$0.535

Open
HK$0.535
Previous close
HK$0.54
Volume
10K
0.03× average
Average volume
327.64K
Average daily volume
Market cap
90.65M HKD
Beta
1.53
Market reference 1
50-day average
HK$0.6397
-16.37% below average
200-day average
HK$0.4506
+18.72% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
-14.36M HKD
P/E (TTM)
22.57×
P/B (TTM)
0.23×
P/S (TTM)
0.2×
EV / EBITDA
-1.94×
Earnings yield
12.75%
Free cash flow yield
83.23%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
3.49%
Operating margin
0.85%
Net margin
0.89%
Return on equity
1.52%
Return on assets
1.45%
Return on invested capital
1.45%

Financial health

Debt / equity
0×
Current ratio
22.62×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends7%0%-7%-14%Gross margin, FY2021: 5.66%Gross margin, FY2022: 3.90%Gross margin, FY2023: -3.70%Gross margin, FY2024: 5.71%Gross margin, FY2025: 3.29%Operating margin, FY2021: -5.67%Operating margin, FY2022: -8.36%Operating margin, FY2023: -5.48%Operating margin, FY2024: 2.68%Operating margin, FY2025: 0.84%Net margin, FY2021: -0.31%Net margin, FY2022: -11.91%Net margin, FY2023: -5.48%Net margin, FY2024: 0.25%Net margin, FY2025: 0.88%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 5.66%. Gross margin FY2022 3.90%. Gross margin FY2023 -3.70%. Gross margin FY2024 5.71%. Gross margin FY2025 3.29%. Operating margin FY2021 -5.67%. Operating margin FY2022 -8.36%. Operating margin FY2023 -5.48%. Operating margin FY2024 2.68%. Operating margin FY2025 0.84%. Net margin FY2021 -0.31%. Net margin FY2022 -11.91%. Net margin FY2023 -5.48%. Net margin FY2024 0.25%. Net margin FY2025 0.88%.

Income trends

Revenue

677.12M HKD+30.29%

Operating income

5.67M HKD-59.28%

Net income

5.94M HKD+353.17%
Income trends across reported periods2.18B HKD1.3B HKD424.92M HKD−453.24M HKDRevenue, FY2021: 283.4M HKDRevenue, FY2022: 1.96B HKDRevenue, FY2023: 961.29M HKDRevenue, FY2024: 519.7M HKDRevenue, FY2025: 677.12M HKDOperating income, FY2021: −16.06M HKDOperating income, FY2022: −163.95M HKDOperating income, FY2023: −52.71M HKDOperating income, FY2024: 13.92M HKDOperating income, FY2025: 5.67M HKDNet income, FY2021: −888K HKDNet income, FY2022: −233.7M HKDNet income, FY2023: −52.71M HKDNet income, FY2024: 1.31M HKDNet income, FY2025: 5.94M HKDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 283.4M HKD. Revenue FY2022 1.96B HKD. Revenue FY2023 961.29M HKD. Revenue FY2024 519.7M HKD. Revenue FY2025 677.12M HKD. Operating income FY2021 −16.06M HKD. Operating income FY2022 −163.95M HKD. Operating income FY2023 −52.71M HKD. Operating income FY2024 13.92M HKD. Operating income FY2025 5.67M HKD. Net income FY2021 −888K HKD. Net income FY2022 −233.7M HKD. Net income FY2023 −52.71M HKD. Net income FY2024 1.31M HKD. Net income FY2025 5.94M HKD.
Metric (HKD)FY2025FY2024FY2023FY2022FY2021
Revenue677.12M HKD519.7M HKD961.29M HKD1.96B HKD283.4M HKD
Cost of goods sold654.86M HKD490.03M HKD996.89M HKD1.89B HKD267.36M HKD
Gross profit22.26M HKD29.67M HKD−35.6M HKD76.48M HKD16.04M HKD
Selling, general, and administrative16.59M HKD15.49M HKD16.75M HKD19.36M HKD20.67M HKD
Operating expenses16.59M HKD76.15M HKD17.1M HKD333.27M HKD20.67M HKD
Interest income484K HKD243K HKD69K HKD100K HKD119K HKD
Interest expense38K HKD23K HKD43K HKD34K HKD508K HKD
Depreciation and amortization1.72M HKD1.72M HKD2.43M HKD2.43M HKD2.44M HKD
Operating income5.67M HKD13.92M HKD−52.71M HKD−163.95M HKD−16.06M HKD
Net income5.94M HKD1.31M HKD−52.71M HKD−233.7M HKD−888K HKD

Company facts updated Aug 24, 2026.

Corporate actions

Corporate action history

Dividend

Ex-dividend May 31, 2018

HK$0.0001

Special

Record Jun 1, 2018 · Payment Jun 27, 2018

Dividend

Ex-dividend Sep 16, 2015

HK$0.0006

Quarterly

Dividend

Ex-dividend May 29, 2015

HK$0.0003

Special

Dividend

Ex-dividend Sep 2, 2014

HK$0.005

Special

0911.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.4

-4.08%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.30

-3.94%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$221.8

-2.72%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.54

-4.82%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.14

-5.86%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$100.5

-1.86%

Continue in GoAI

Research 0911.HK

research.disclaimer